Ciclopirox Provides Relief For Patients With Seborrheic Dermatitis

Ciclopirox Provides Relief For Patients With Seborrheic Dermatitis

CiclopiroxCiclopirox is an effectual topical treatment of seborrheic dermatitis of the scalp for adults. Known as the brand Loprox, the patent for this antifungal shampoo expires on Sept 16, 2017. Seborrheic dermatitis is a common skin disorder that affects the scalp and causes scaly, itchy, red skin as well as stubborn dandruff. Thought to be caused by a combination of irritation from a yeast called malassezia and an over production of skin oil, seborrheic dermatitis has shown to run in families. Additional risk factors for this inflammatory skin condition include neurologic conditions, including Parkinson’s disease, stress, oily skin, head injury, stroke, acne and obesity. While seborrheic dermatitis is not a fatal condition, secondary bacterial or fungal infections can form if this condition is left untreated. In addition, patients with seborrheic dermatitis often experience great psychological distress and embarrassment, as well as low self-esteem.

Patients should apply approximately 5 ml, or one teaspoonful of Ciclopirox shampoo to wet hair, directly on the scalp. After lathering the treatment should be left on for three minutes and rinsed out thoroughly. Typically this treatment should be administered two times per week for four weeks total. At least three days should pass between treatment applications.The brand Loprox, Ciclopirox is available as a 1% solution in a 120 ml plastic bottle.

Ciclopirox shampoo was shown to be statistically significantly more effective in many studies. One such study, which was comprised of two double-blind and randomized clinical trials, involved patients ages 16 and older who had seborrheic dermatitis. Participants were given Ciclopirox shampoo, or a placebo to be used two times per week for four weeks. The patients who received Ciclopirox (Loprox) reported response rates of 58% and 26%, respectively, compared with 31% and 13% for the patients who were given a placebo.

LGM Pharma provides the Ciclopirox CAS# 29342-05-0 API along with continuous support to clients for research and development purposes.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service